TY - JOUR
T1 - Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
AU - Kumar, Shaji K.
AU - Uno, Hajime
AU - Jacobus, Susanna J.
AU - Van Wier, Scott A.
AU - Ahmann, Greg J.
AU - Henderson, Kimberly J.
AU - Callander, Natalie S.
AU - Haug, Jessica L.
AU - Siegel, David S.
AU - Greipp, Philip R.
AU - Fonseca, Rafael
AU - Rajkumar, S. Vincent
PY - 2011/10/20
Y1 - 2011/10/20
N2 - Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio ∇ 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.
AB - Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio ∇ 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.
UR - http://www.scopus.com/inward/record.url?scp=80054840882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054840882&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-03-342089
DO - 10.1182/blood-2011-03-342089
M3 - Article
C2 - 21860025
AN - SCOPUS:80054840882
SN - 0006-4971
VL - 118
SP - 4359
EP - 4362
JO - Blood
JF - Blood
IS - 16
ER -